GlaxoSmithKline (CAI:BIOC) Loans Receivable: E£0 Mil (As of Sep. 2016)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is GlaxoSmithKline Loans Receivable?

GlaxoSmithKline CAI:BIOC -3.98% Loans Receivable is E£0 Mil as of Sep. 2016.

GlaxoSmithKline's Loans Receivable for the quarter that ended in Sep. 2016 was E£0 Mil.

GlaxoSmithKline Loans Receivable Related Terms

GlaxoSmithKline Loans Receivable Historical Data

* Premium members only.

The historical data trend for GlaxoSmithKline's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Loans Receivable Chart

GlaxoSmithKline Annual Data
Trend Dec12 Dec13 Dec14 Dec15
Loans Receivable
0.00 0.00 0.00 0.00

GlaxoSmithKline Quarterly Data
Dec12 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

GlaxoSmithKline Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of E£0 Mil mean?
GlaxoSmithKline (CAI:BIOC) has a Loans Receivable of E£0 Mil as of Sep. 2016. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on GlaxoSmithKline and its competitors.
Is GlaxoSmithKline's Loans Receivable too high?
GlaxoSmithKline's current Loans Receivable is E£0 Mil.
How does GlaxoSmithKline's Loans Receivable compare to PRPH?
GlaxoSmithKline's Loans Receivable of E£0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Drug Manufacturers company?
A good Loans Receivable depends on the Drug Manufacturers industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on GlaxoSmithKline and its competitors. GlaxoSmithKline's current Loans Receivable is E£0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline stock overvalued right now?
GlaxoSmithKline (CAI:BIOC) has a current Loans Receivable of E£0 Mil. The current Loans Receivable is E£0 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For GlaxoSmithKline (CAI:BIOC), the current Loans Receivable is E£0 Mil as of Sep. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GlaxoSmithKline Business Description

Address Boomerang Building, No 46, Block (J) First Section City Centre, Town Centre, Second floor, Fifth District - New Cairo, Cairo, EGY, 11835
GlaxoSmithKline is a pharmaceutical company. It is focused on developing new medicines in respiratory, HIV, oncology, and immune-inflation. The company is segmented into Commercial Operations and Total Research and development. It generates the majority of its revenue from the Commercial Operations segment.